Sionna Financial Statements From 2010 to 2026

SION Stock   33.15  1.42  4.11%   
Sionna Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sionna Therapeutics' valuation are provided below:
Market Capitalization
1.5 B
Earnings Share
(1.80)
We have found ninety-six available fundamental trend indicators for Sionna Therapeutics Common, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sionna Therapeutics' current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Sionna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sionna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.9 M, Interest Income of 9.9 M or Depreciation And Amortization of 503.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.63. Sionna financial statements analysis is a perfect complement when working with Sionna Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Sionna Stock
Check out the analysis of Sionna Therapeutics Correlation against competitors.

Sionna Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets179 M326 M110.5 M
Slightly volatile
Other Current Liabilities8.8 M9.7 M7.8 M
Slightly volatile
Total Current Liabilities10.6 M11.7 M8.7 M
Slightly volatile
Property Plant And Equipment Net9.3 M9.2 M4.3 M
Slightly volatile
Accounts Payable888.5 K769 K635.5 K
Slightly volatile
Cash52.1 M58.5 M52.9 M
Slightly volatile
Non Current Assets Total88.8 M84.5 M15.7 M
Slightly volatile
Non Currrent Assets Other79.2 M75.4 M10.1 M
Slightly volatile
Cash And Short Term Investments138.8 M235.9 M96.2 M
Slightly volatile
Common Stock Shares Outstanding34.5 M40 M43.3 M
Slightly volatile
Liabilities And Stockholders Equity179 M326 M110.5 M
Slightly volatile
Non Current Liabilities TotalM7.4 M144.1 M
Pretty Stable
Other Current AssetsM5.5 M1.7 M
Slightly volatile
Total Liabilities18.2 M19.1 M152.8 M
Pretty Stable
Property Plant And Equipment Gross10.1 M13.6 M5.1 M
Slightly volatile
Total Current Assets141.7 M241.4 M97.8 M
Slightly volatile
Capital Stock3.3 K5.8 K2.5 K
Slightly volatile
Net Working Capital90.7 M161.7 M82.7 M
Slightly volatile
Common Stock47.2 K45 K7.4 K
Slightly volatile
Short and Long Term Debt Total7.7 M8.7 M10.2 M
Slightly volatile
Short Term Debt1.1 M1.3 M803.4 K
Slightly volatile

Sionna Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income9.9 M9.4 M2.6 M
Slightly volatile
Interest Income9.9 M9.4 M2.6 M
Slightly volatile
Depreciation And Amortization503.4 K768.2 K241.7 K
Slightly volatile
Selling General Administrative16.1 M28.7 M9.2 M
Slightly volatile
Other Operating Expenses59.5 M81.1 M47 M
Slightly volatile
Research Development53 M60.3 M38.9 M
Slightly volatile
Total Operating Expenses68.9 M89 M48 M
Slightly volatile
Reconciled Depreciation503.4 K768.2 K241.7 K
Slightly volatile
Total Other Income Expense Net7.4 M13.7 M2.8 M
Slightly volatile
Cost Of Revenue534.4 K601.2 K656.2 K
Slightly volatile

Sionna Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation12.7 M12.1 M3.1 M
Slightly volatile
Begin Period Cash Flow39.7 M38.8 M18.1 M
Slightly volatile
Other Cashflows From Financing Activities136.3 M205.7 M115.4 M
Pretty Stable
Capital Expenditures678.8 K377 K1.6 M
Slightly volatile
Total Cash From Financing Activities136.3 M205.7 M115.4 M
Pretty Stable
End Period Cash Flow53.2 M59.4 M53.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Payables Turnover0.560.84140.5794
Slightly volatile
Cash Per Share6.25.90262.3916
Slightly volatile
Days Payables Outstanding595434632
Slightly volatile
Income Quality0.980.88080.8996
Pretty Stable
Net Debt To EBITDA0.810.66131.1599
Slightly volatile
Current Ratio21.6420.61311.3926
Slightly volatile
Capex Per Share0.0090.00940.0351
Slightly volatile
Interest Debt Per Share0.250.21710.236
Pretty Stable
Debt To Assets0.02530.02660.1722
Slightly volatile
Days Of Payables Outstanding595434632
Slightly volatile
Ebt Per Ebit1.00.84590.959
Slightly volatile
Long Term Debt To Capitalization0.01890.02120.0232
Slightly volatile
Quick Ratio21.6420.61311.3926
Slightly volatile
Cash Ratio5.514.99076.194
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00571.0487
Pretty Stable
Debt Ratio0.02530.02660.1722
Slightly volatile

Sionna Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.5 B1.6 B
Slightly volatile
Enterprise Value1.3 B1.4 B1.6 B
Slightly volatile

Sionna Fundamental Market Drivers

About Sionna Therapeutics Financial Statements

Sionna Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Sionna Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue601.2 K534.4 K

Pair Trading with Sionna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sionna Stock

  0.69OSE OSE Pharma SAPairCorr

Moving against Sionna Stock

  0.67VALN Valneva SE ADRPairCorr
  0.458VP1 AVRICORE HEALTH INCPairCorr
  0.44EQ EquilliumPairCorr
  0.37JUMP Leveljump Healthcare CorpPairCorr
  0.35DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Sionna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics Common to buy it.
The correlation of Sionna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sionna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sionna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sionna Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sionna Therapeutics Common Stock:
Check out the analysis of Sionna Therapeutics Correlation against competitors.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.80)
Return On Assets
(0.22)
Return On Equity
(0.32)
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.